Abstract 94P
Background
Thirty percent of patients with early-stage NSCLC are treated without a pathological diagnosis. With upcoming neoadjuvant immuno- and targeted therapies it is important to complete a molecular diagnosis before treatment. Bronchoalveolar lavage fluid (BALF) is easily collected and minimal invasive but has poor diagnostical yield in standard cytological work-up. A potential new diagnostic tool could be detection of circulating tumor DNA (ctDNA), in which genetic and epigenetic alterations of the tumor can be detected. The aim of this study is to determine if cell free (cfDNA) analysis in BALF is representative for the molecular diagnosis in NSCLC.
Methods
49 BALF samples of patients with suspected NSCLC have been analyzed. During the routine bronchoscopy or EBUS, bronchoalveolar lavage was performed in the affected lobe and usual material for routine diagnostics was obtained. Samples were analyzed using the Oncomine PAN-Cancer Cell-free NGS panel and the molecular results were compared.
Results
Analysis has been done on 53 patients. In 42 patients a molecular alteration was found. In 79% of the cases the cfDNA analysis of the BALF was completely or partly representative. In 12 patients a molecular alteration was found in BALF while this was not found with a regular endoscopy (bronchoscopy and or EBUS). After more diagnostics (eg CT guided biopsy) 18 patients did not have a cyto-or histopathological molecular result pretreatment, 6 of those had a positive BALF cfDNA result. BALF analysis reduced the number of patients in this cohort without a pretreatment molecular diagnosis by a third.
Conclusions
In conclusion, cfDNA from BALF as a source for molecular diagnostics is highly comparable with routine diagnostic material and could reduce the number of patients treated without a molecular diagnosis. Furthermore, BALF is easily obtained, and the procedure is relatively minimal invasive. In 10 cases the only pathogenic variant found in BALF is a TP53 mutation. When only a TP53 mutation is found, no hard conclusions can be drawn regarding the origin of the tumor and thus the diagnosis NSCLC, since TP53 is also often found in other malignancies. As long as this is considered, BALF could be an additional diagnostic tool for patients with NSCLC.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Team Westland.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract